ReviewFrontiers in immunology
Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in".
Review in Frontiers in immunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.
- Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.Expert review of anti-infective therapy · 2022Pooled it
- Ischemic modified albumin and thiol levels in Coronavirus disease 19: a systematic review and meta-analysis.Diagnostic and prognostic research · 2025Review
- Molecular dynamics simulation and docking studies reveals inhibition of NF-kB signaling as a promising therapeutic drug target for reduction in cytokines storms.Scientific reports · 2025Article
- Success of intravenous immunoglobulin and steroids in managing severe COVID-19 following lung transplantation: A case report.World journal of transplantation · 2025Article
- Vitamin D: Evidence-Based Health Benefits and Recommendations for Population Guidelines.Nutrients · 2025Review
- COVID-19: Lessons Learned from Molecular and Clinical Research.International journal of molecular sciences · 2025Article
- Predicting Intensive Care Unit Admission in COVID-19-Infected Pregnant Women Using Machine Learning.Journal of clinical medicine · 2024Article
- Cytokine landscape in hospitalized children with multisystem inflammatory syndrome.Scientific reports · 2024Article
- Role of Vaccination Strategies to Host-Pathogen Dynamics in Social Interactions.Entropy (Basel, Switzerland) · 2024Article
- Diverse roles of SARS-CoV-2 Spike and Nucleocapsid proteins in EndMT stimulation through the TGF-β-MRTF axis inhibited by aspirin.Cell communication and signaling : CCS · 2024Article
- Pro-Inflammatory and Anti-Inflammatory Interleukins in Infectious Diseases: A Comprehensive Review.Tropical medicine and infectious disease · 2024Review
- COVID-19: Not a thrombotic disease but a thromboinflammatory disease.Upsala journal of medical sciences · 2024Review
- COVID-19 Pneumonia and Cytokine Storm Syndrome.Advances in experimental medicine and biology · 2024Review
- SARS-CoV-2 Nsp15 suppresses type I interferon production by inhibiting IRF3 phosphorylation and nuclear translocation.iScience · 2023Article
- Meta-analysis of the impact of physical activity on the recovery of physical function in COVID-19 patients.Heliyon · 2023Review
- Immunomodulatory approaches in managing lung inflammation in COVID-19: A double-edge sword.Immunity, inflammation and disease · 2023Review
- Infection, Dysbiosis and Inflammation Interplay in the COVID Era in Children.International journal of molecular sciences · 2023Review
- Analysis of Ischemia-Modified Albumin (IMA) and Coagulation Parameters in Patients with SARS-CoV-2 Pneumonia.Journal of clinical medicine · 2023Article
- Inflammation and Immune Reactions in the Fetus as a Response to COVID-19 in the Mother.Journal of clinical medicine · 2023Article
- Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In December 2019, a novel coronavirus, COVID-19, was discovered to be the causal agent of a severe respiratory infection named SARS-CoV-2, and it has since been recognized worldwide as a pandemic. There are still numerous doubts concerning its pathogenesis and particularly the underlying causes of the various clinical courses, ranging from severe manifestations to asymptomatic forms, including acute respiratory distress syndrome. The major factor responsible for acute respiratory distress syndrome is the so-called "cytokine storm," which is an aberrant response from the host immune system that induces an exaggerated release of proinflammatory cytokines/chemokines. In this review, we will discuss the role of cytokine storm in COVID-19 and potential treatments with which counteract this aberrant response, which may be valuable in the clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.